Valuation: Vivos Therapeutics, Inc.

Market Cap 3.22M 2.81M 2.64M 2.41M 4.52M 309M 4.52M 31.68M 12.21M 157M 12.1M 11.83M 507M P/E 2026 *
-0.12x
P/E 2027 * -0.19x
Enterprise Value 3.22M 2.81M 2.64M 2.41M 4.52M 309M 4.52M 31.68M 12.21M 157M 12.1M 11.83M 507M EV / Sales 2026 *
0.15x
EV / Sales 2027 * 0.09x
Free-Float
88%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week-9.39%
Current month-18.32%
1 month-46.09%
3 months-67.98%
6 months-86.88%
Current year-92.11%
1 week 0.16
Extreme 0.1559
0.18
1 month 0.16
Extreme 0.1559
0.46
Current year 0.16
Extreme 0.1559
2.69
1 year 0.16
Extreme 0.1559
3.58
3 years 0.16
Extreme 0.1559
48.79
5 years 0.16
Extreme 0.1559
118
10 years 0.16
Extreme 0.1559
360.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 2016-08-31
Chief Executive Officer 68 2016-08-31
Director TitleAgeSince
Chairman 68 2020-05-31
Director/Board Member 87 2020-05-31
Director/Board Member 59 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 Other

Director

12,000 0.0596%
9/14/26 Free

Director

12,000 0.0596%
7/31/26 Free

Chief Financial Officer

400,000 2.8788%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-9.39%-95.35%-96.92% 3.28M
+0.37%-0.34%+24.72%+27.33% 12.51B
+1.95%+1.18%+14.23%+21.31% 6.52B
-3.07%-3.87% - - 6.13B
-0.21%+0.74%+28.03%+21.61% 5.54B
+1.45%-1.93%-19.10%+39.08% 4.99B
+0.61%+3.41%-32.04%-22.44% 3.9B
-0.96%+1.91%+30.26%-6.03% 1.94B
-3.52%-5.74%-20.47%+168.07% 1.71B
-1.95%+0.60%+48.74%-15.31% 1.57B
Average -0.72%-0.81%-2.33%+15.19% 4.48B
Weighted average by Cap. -0.09%-0.10%+11.30%+24.81%

Financials

2026 *2027 *
Net sales 21.79M 19M 17.89M 16.29M 30.55M 2.09B 30.59M 214M 82.59M 1.06B 81.85M 80.03M 3.43B 34.09M 29.72M 27.99M 25.49M 47.8M 3.27B 47.86M 335M 129M 1.66B 128M 125M 5.37B
Net income -23.53M -20.52M -19.33M -17.6M -33M -2.25B -33.04M -231M -89.2M -1.15B -88.4M -86.44M -3.71B -14.7M -12.82M -12.07M -11M -20.62M -1.41B -20.64M -145M -55.73M -718M -55.23M -54.01M -2.32B
Net Debt - -
Logo Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
Employees
268
Date Price Change Volume
26-09-21 US$0.1601 -1.90% 665,434
26-09-18 US$0.1632 -7.27% 1,668,001
26-09-17 US$0.1760 +9.25% 1,820,013
26-09-16 US$0.1611 -1.53% 1,366,101
26-09-15 US$0.1636 -7.41% 1,558,577
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.1601USD
Average target price
2.117USD
Spread / Average Target
+1,222.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VVOS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!